China
Africa
Explore chapters and articles related to this topic
Eczema (dermatitis)
Published in Rashmi Sarkar, Anupam Das, Sumit Sethi, Concise Dermatology, 2021
Steroid formulations specifically tested for safety and approved by the US Federal Drug Administration (FDA) for use in younger children include desonide hydrogel and nonethanolic foam, fluticasone 0.05% cream, and fluocinolone acetonide oil. Mometasone cream and ointment are approved for children aged 2 years and older. Ointments are preferred over creams, lotions, and gels as vehicles for steroids, as they do not contain preservatives and tend to have a better emollient effect.
Ayurveda Renaissance – Quo Vadis?
Published in D. Suresh Kumar, Ayurveda in the New Millennium, 2020
For example, the leaves of the neem tree (Azadirachta indica) are traditionally used as an anti-inflammatory drug. The leaves contain isoazadirolide, a bioactive molecule with very little information available in literature (Siddiqui et al. 1986). Isoazadirolide was linked in the network to two synthetic compounds, namely desonide and fluocinonide. Desonide is a topical agent for dermatoses, while fluocinonide is a topical glucocortisoid used in the treatment of eczema (Brogden et al. 1974; Bhankharia and Sanjana 2004).
Topical Agents
Published in John Y. M. Koo, Ethan C. Levin, Argentina Leon, Jashin J. Wu, Alice B. Gottlieb, Moderate to Severe Psoriasis, 2014
Rosemary deShazo, Gerald G. Krueger, Kristina Callis Duffin
Foam Three corticosteroids are available in the United States as a foam: clobetasol propionate (Olux® and Olux-E®), betamethasone valerate (Luxiq®), and desonide (Verdeso®). Olux and Luxiq both have a thermolabile formulation with ethanol, and cetyl and stearyl alcohol, which allows for rapid drying and no residue after application. Clobetasol foam resulted in clearance or near-clearance of scalp psoriasis in 74% of patients in one study [26] and has also been shown to be efficacious in the treatment of body plaques [27]. A study conducted by Bergstrom et al. showed that clobetasol foam was superior to clobetasol cream and was a solution for treatment of body and scalp plaques by the Psoriasis Area and Severity Index (PASI), quality of life measures, clearance of scalp lesions, and in time of application [24]. Although the foam vehicle is often not prescribed due to its cost, this study showed there were no significant differences in cost after controlling for body surface area. The Olux-E formulation, which primarily differs from Olux by the absence of ethanol and the addition of cyclomethicone and white petrolatum, also has efficacy in plaque psoriasis [28,29]. Betamethasone valerate foam was shown to clear or nearly clear scalp psoriasis in 72% of patients and was preferred by patients over the lotion vehicle [30]. In the United States, desonide foam is indicated for treatment of moderate to severe atopic dermatitis in adults and in children as young as three months of age [31]. It could be considered for off-label use in psoriasis (if a foam vehicle is preferred) when low potency corticosteroid is indicated.
Clinical efficacy analysis of 110 cases of childhood vitiligo with non-surgical combined therapy
Published in Journal of Dermatological Treatment, 2022
Yuan-Yuan Liu, Jun-Feng Zhou, Yu Zhen, Yan Cui, Yang Song, Lei Yao, Shan-Shan Li
We used combination therapy (TCI, TCS, NB-UVB and SC) that was tailored to each patient’s disease condition. When pediatric vitiligo was progressing, TCI/TCS and NB-UVB therapy were provided. If the disease progressed rapidly or TCI/TCS and phototherapy could not control the disease activity, a short-term SC was prescribed. The TCS was administered with desonide cream 0.05% twice daily for children younger than 2 years or mometasone furoate 0.1% was administered once daily or every other day for older children. The TCI (tacrolimus 0.03% ointment or pimecrolimus 1% cream) was used twice daily for children ≥2 years old. The NB-UVB device was used as a hand-held, home-based phototherapy device (SIGMA SH1B) thrice weekly on alternate days (11,12), and we have developed a unified protocol: the initial dose was 200mJ/cm2, with increments of 20% in every dose, up to a maximum of 1500mJ/cm2 to face, 3000mJ/cm2 to the body, and 5000mJ/cm2 to acrofacial. The SC was administered as follows: oral prednisolone (0.3 mg/kg) daily or prednisolone at 1 mg/kg body weight twice weekly on 2 consecutive days until the disease was stable (13,14). When the disease was stable or in the maintenance stage, patients received TCI (twice weekly) combined with NB-UVB therapy or NB-UVB therapy alone (<2 years old) (11,15).
Development of a nanotechnological hydrogel containing desonide nanocapsules in association with acai oil: design and in vivo evaluation
Published in Pharmaceutical Development and Technology, 2022
Priscila Rosa, Mariane Lago Friedrich, Juliana dos Santos, Natháli Schopf Pegoraro, Camila Camponogara, Sara Marchesan Oliveira, Cristiane de Bona da Silva, Andréa Inês Horn Adams
Topical glucocorticoids (TG) are among the most common drugs prescribed by dermatologists (Senyiğit et al. 2009) for the treatment of psoriasis and atopic dermatitis (Aubert-Wastiaux et al. 2011). The clinical efficacy of these drugs is related to their anti-inflammatory, immunosuppressive, vasoconstrictive and anti-proliferative effects (Grau 2006; Senyiğit et al. 2009). Desonide is a low potency synthetic non-fluorinated glucocorticoid used for the treatment of sensitive areas such as the face and intertriginous region, in the elderly and children (Kahanek et al. 2008; Horn et al. 2010). Despite the clinical efficacy of this class of drugs in therapy of inflammatory diseases TG can induce local and systemic side effects. Skin reactivity, telangiectasia, atrophy and hypopigmentation are common local side effects induced by these compounds. Among the systemic side effects induced by TG are endocrine effects, such as Cushing syndrome, metabolic events such as hyperglycemia and adrenocortical suppression and electrolyte balance disturbances, which can cause edema and hypertension (Beltrani et al. 2005; Hengge et al. 2006).
The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome
Published in Ocular Immunology and Inflammation, 2019
Carlo Alberto Cutolo, Stefano Barabino, Chiara Bonzano, Carlo Enrico Traverso
As is difluprednate, desonide is also a corticosteroid originally developed for dermatologic applications. The molecule is marketed in some countries as desonide-21-disodium phosphate ophthalmic ointment 0.25% and desonide-21-disodium phosphate 0.25% ophthalmic solution. There are no formulations of the drug currently FDA-approved for ophthalmic use, and there are not ongoing clinical trials. Desonide-21-disodium phosphate is a nonfluorinated corticosteroid with a nonsymmetric 16, 17-acetyl substitution and a supposed low ocular penetration and absorption. The molecule has been successfully used to treat allergic conjunctivitis without a significant increase in IOP.71 RCTs are needed to evaluate the role of desonide in the management of DED patients.